Comparing Two New Myeloma Treatments: JNJ-79635322 vs Teclistamab
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study compares two new antibody-based drugs (JNJ-79635322 and teclistamab) to see which works better for multiple myeloma that has come back or stopped responding to prior treatment. Both drugs are designed to help your immune system fight myeloma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of multiple myeloma with measurable disease detectable by lab tests
- Received 1 to 3 prior treatment regimens, including at least one anti-CD38 antibody (like daratumumab) and lenalidomide
- Good overall health and functioning (able to care for yourself with minimal assistance; ECOG score 0–2)
- Blood work and organ function meet study safety requirements at screening and before starting treatment
- No major surgery or significant injury in the past 2 weeks, and fully recovered before starting the study drug
- No other active cancers, history of certain blood cancers, or brain/spinal cord involvement of myeloma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (JNJ-79635322) compared to another targeted immunotherapy (Teclistamab) for people with multiple myeloma that has returned or not responded after several prior treatments.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.